Studies of the Toxicological Potential of Capsinoids, XIII: Inhibitory Effects of Capsaicin and Capsinoids on Cytochrome P450 3A4 in Human Liver Microsomes

International Journal of Toxicology

Volumn 29, Issue 2_suppl, 2010, Pages 22S-26S

  Takanohashi, Toshiyuki ^a   Isaka, Mitsuyoshi ^a   Ubukata, Kazuyuki ^a   Mihara, Ryuichi ^a   Bernard, Bruce K ^b  

^a AJINOMOTO CO INC   (Japan)

^b GENERAL DYNAMICS   (United States)

Author keywords

capsaicin; capsinoids; cytochrome P450 3A4; human liver microsomes

Indexed keywords

CAPSAICIN; CAPSIATE; CAPSINOID; CYTOCHROME P450 3A4; DIHYDROCAPSIATE; KETOCONAZOLE; MIDAZOLAM; NORDIHYDROCAPSIATE; OXIDOREDUCTASE INHIBITOR; TOLBUTAMIDE; UNCLASSIFIED DRUG; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; DRUG DERIVATIVE; ENZYME INHIBITOR;

ARTICLE; CHEMICAL STRUCTURE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIVER MICROSOME; SUICIDE SUBSTRATE; ADULT; AGED; CHILD; DRUG ANTAGONISM; ENZYMOLOGY; FEMALE; MALE; MIDDLE AGED; PRESCHOOL CHILD;

ADULT; AGED; CAPSAICIN; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP3A; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MICROSOMES, LIVER; MIDDLE AGED;

EID: 77955073658     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1177/1091581809360282     Document Type: Article

References (31)

1. Cordell GA, Araujo OE. Capsaicin: identification, nomenclature, and pharmacotherapy. Ann Pharmacother. 1993;27:330-336
2. Kobata K, Todo T, Yazawa S, et al. Novel capsaicinoid-like substances, capsiate and dihydrocapsiate, from the fruits of a nonpungent cultivar, CH-19 Sweet, of pepper (Capsicum annuum L.). J Agric Food Chem. 1998;46:1695-1697
3. Kobata K, Sutoh K, Todo T, et al. Nordihydrocapsiate, a new capsinoid from the fruits of a nonpungent pepper, capsicum annuum. J Nat Prod. 1999;62:335-336
4. Dib B. Effects of intrathecal capsaicin on autonomic and behavioral heat loss responses in the rat. Pharmacol Biochem Behav. 1987;28:65-70
5. Kawada T, Hagihara K, Iwai K. Effects of capsaicin on lipid metabolism in rats fed a high fat diet. J Nutr. 1986;116: 1272-1278
6. Ohnuki K, Haramizu S, Oki K, et al. Administration of capsiate, a non-pungent capsaicin analog, promotes energy metabolism and suppresses body fat accumulation in mice. Biosci Biotechnol Biochem. 2001;65:2735-2740
7. Ohnuki K, Niwa S, Maeda S, et al. CH-19 Sweet, a non-pungent cultivar of red pepper, increased body temperature and oxygen consumption in humans. Biosci Biotechnol Biochem. 2001;65: 2033-2036
8. Bernard BK, Tsubuku S, Kayahara T, et al. Studies of the toxicological potential of capsinoids, X: safety assessment and pharmacokinetics of capsinoids in healthy male volunteers after a single oral ingestion of CH-19 Sweet extract. Int J Toxicol. 2008; 27(suppl 3):137-147
9. Bernard BK, Watanabe E, Kodama T, et al. Studies of the toxicological potential of capsinoids, IV: teratology studies of CH-19 Sweet extract in rats and rabbits. Int J Toxicol. 2008;27(suppl 3):41-58
10. Kodama T, Watanabe E, Masuyama T, et al. Studies of the toxicological potential of capsinoids II: a 26-week daily gavage toxicity study of CH-19 Sweet extract in rats. Int J Toxicol. 2008;27(suppl 3):11-28
11. Kodama T, Watanabe E, Masuyama T, et al. Studies of the toxicological potential of capsinoids, III: a two-generation reproduction study of CH-19 Sweet extract in rats. Int J Toxicol. 2008; 27(suppl 3):29-40
12. Watanabe E, Kodama T, Masuyama T, et al. Studies of the toxicological potential of capsinoids, I: single dose toxicity study and genotoxicity studies of CH-19 Sweet extract. Int J Toxicol. 2008; 27(suppl 3):1-10
13. Bernard BK, Watanabe E, Kodama T, et al. Studies of the toxicological potential of capsinoids, V: genotoxicity studies in dihydrocapsiate. Int J Toxicol. 2008;27(suppl 3):59-72
14. Bernard BK, Watanabe E, Kodama T, et al. Studies of the toxicological potential of capsinoids, IX: teratology studies of dihydrocapsiate in rats and rabbits. Int J Toxicol. 2008;27(suppl 3):119-136
15. Kodama T, Masuyama T, Kayahara T, et al. Studies of the toxicological potential of capsinoids, XIV: a 26-week gavage toxicity study of dihydrocapsiate in rats. Int J Toxicol. 2010; 29(suppl 1):27S-54S
16. Kodama T, Watanabe E, Tsubuku S, et al. Studies of the toxicological potential of capsinoids, VII: a 13-week gavage toxicity study of dihydrocapsiate in rats. Int J Toxicol. 2008;27(suppl 3):79-100
17. Watanabe E, Kodama T, Masuyama T, et al. Studies of the toxicological potential of capsinoids, VI: single dose toxicity study and micronucleus test of commercial grade dihydrocapsiate. Int J Toxicol. 2008;27(suppl 3):73-78
18. Watanabe E, Kodama T, Masuyama T, et al. Studies of the toxicological potential of capsinoids, VIII: a 13-week toxicity study of commercial grade dihydrocapsiate in rats. Int J Toxicol. 2008;27(suppl 3):101-118
19. Bernard BK, Ubukata K, Mihara R, et al. Studies of the toxicological potential of capsinoids, XI: pharmacokinetic study of 14Cdiydrocapsiate (a capsinoid) in rats. Int J Toxicol. 2010; 29(suppl 1):3S-14S
20. Shirai Y, Ueno S, Nakayama A, et al. Studies of the toxicological potential of capsinoids, XII: a pharmacokinetic study of capsinoid-containing CH-19 Sweet extract in rats. Int J Toxicol. 2010;29(suppl 1):15S-21S
21. Reilly CA, Ehlhardt WJ, Jackson DA, et al.Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003;16:336-349
22. Joel GH, Lee EL, Alfred GG, et al. In: Goodman LS, Gilman A, eds. The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill; 2001
23. Ito K, Iwatsubo T, Kanamitsu S, et al. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev. 1998;50:387-412
24. Ito K, Ogihara K, Kanamitsu S, et al. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos. 2003;31: 945-954
25. Yuan R, Madani S, Wei XX, et al. Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos. 2002; 30:1311-1319
26. Ikeda T, Nishimura K, Taniguchi T, et al. In vitro evaluation of drug interaction caused by enzyme inhibition. Yakubutsu Dotai. 2001;16:115-126
27. Kawahara I, Kato Y, Suzuki H, et al. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)- indanyl]-5-[2(S)-(1,1-dimethylethylaminocarbonyl)-4-[(furo[2,3- b]pyridin-5-yl)methyl] piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethylpentanamide and P-glycoprotein by valspodar in gene transfectant systems. Drug Metab Dispos. 2000;28:1238-1243
28. Lin T, Pan K, et al. In vitro assessment of cytochrome P450 inhibition: strategies for increasing LC/MS-based assay throughput using a one-point IC50 method and multiplexing high-performance liquid chromatography. J Pharm Sci. 2007;96:2485-2493
29. Zhang Z, Hamilton SM, Stewart C. Inhibition of liver microsomal cytochrome P450 activity and metabolism of the tobacco-specific nitrosamine NNK by capsaicin and ellagic acid. Anticancer Res. 1993;13:2341-2346
30. Niwa T, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull. 2005;28:1805-1808
31. Surh Y, Lee SS. Capsaicin, a double-edged sword: toxicity, metabolism, and chemopreventive potential. Life Sci. 1995;56:1845-1855